HistoSonics

By A2Hub Editorial. Published 2026-04-22. Last updated: 2026-04-22.

At a glance

• Founded: 2009
• Founding institution: University of Michigan (biomedical engineering and clinical faculty)
• HQ: Plymouth, Michigan (with U-M scientific roots and Michigan Medicine clinical collaboration)
• Headcount: Growth-stage; specific 2026 headcount not publicly disclosed
• Funding / valuation: Majority-stake recapitalization in 2024 valued the company at $1B+
• Investors in 2024 recap: K5 Global (lead), Bezos Expeditions, Wellington Management
• Regulatory: Edison System received FDA De Novo clearance October 2023 for non-invasive destruction of liver tumors
• Status: Private; commercial-stage with installed base across 50+ US medical centers
• Website: histosonics.com

The U-M-rooted medtech that put Michigan back on the unicorn board

HistoSonics is the reason Michigan added a new tech unicorn to the board in 2024. The company was founded out of the University of Michigan in 2009, commercialized a non-invasive focused ultrasound technique called histotripsy, and cleared the FDA in October 2023 with its Edison system. A 2024 majority-stake recapitalization led by K5 Global with participation from Bezos Expeditions and Wellington Management valued the company above $1B.

That sequence (U-M biomedical engineering research, more than a decade of preclinical and clinical development, FDA De Novo authorization, then unicorn-stage capitalization) is the canonical Michigan medtech path. HistoSonics is the most valuable currently active example of it.

Founding story: the histotripsy program at U-M

HistoSonics was founded in 2009 at the University of Michigan, where a cluster of biomedical engineering faculty and clinicians had been working for more than a decade on the physics of tightly focused ultrasound pulses. The core scientific insight came out of the U-M biomedical engineering program, and the clinical translation involved Michigan Medicine radiology, surgery, and oncology faculty.

For the Ann Arbor tech narrative, HistoSonics belongs in the same conversation as the other U-M medtech exits: HandyLab ($275M to BD in 2009), Accuri Cytometers ($205M to BD in 2011), and NeuMoDx (QIAGEN in 2020). It is the largest and most valuable of the group on a current valuation basis.

The company's corporate headquarters moved to Plymouth, Michigan, which is a short drive east of Ann Arbor, as it matured into a device manufacturer. That is a normal pattern for medtech companies at the clinical and manufacturing scale HistoSonics has reached: the scientific center stays in Ann Arbor and clinical collaboration runs through Michigan Medicine, while manufacturing and field service operations sit in a more industrial-friendly site nearby. The U-M and Michigan Medicine connection has remained continuous through the company's growth.

Clinical traction had been building for years before the 2023 clearance. As of the most recent public updates, HistoSonics and partner clinical sites had treated more than 2,000 patients, and the Edison system had been installed at 50-plus US medical centers. That installed base is what converts a novel platform into a repeatable commercial business.

The 2024 majority-stake recapitalization was the signature event. K5 Global led, with Bezos Expeditions and Wellington Management participating, and the transaction valued the company above $1B. K5 Global is a Michael Kives-led vehicle that has been building a portfolio of late-stage private growth companies. Bezos Expeditions is Jeff Bezos' personal investment office. Wellington is one of the largest institutional asset managers in the world. That investor mix signals both a late-stage capitalization and a premium-quality cap table that a number of growth companies would envy.

What they build

HistoSonics commercializes a new therapeutic modality. Not a device that marginally improves an existing workflow. A new category.

The underlying technique is histotripsy. Short, high-amplitude ultrasound pulses are aimed at a precise point deep inside tissue. Those pulses create and collapse microscopic clouds of cavitation bubbles. The bubbles mechanically liquefy the target at the cellular level. The surrounding tissue is not thermally damaged, and no incision is required. The body clears the debris on its own over time.

Unlike traditional high-intensity focused ultrasound (HIFU), which relies on heating, histotripsy's mechanical mechanism produces a sharply defined treatment zone. That precision is what makes a regulated device feasible. The team at U-M spent more than a decade translating the physics out of the lab through preclinical work, into human trials, and into a device that passed FDA review.

The Edison system is the commercial platform. It is an integrated robotic ultrasound device that uses real-time imaging to plan and guide histotripsy treatments. A clinician identifies a tumor, the system maps the target, and the device delivers the pulses that mechanically destroy the tissue at the focal point. Treatment is non-invasive and incisionless.

The first FDA-cleared indication, via De Novo authorization in October 2023, covers the non-invasive destruction of liver tumors. The liver indication is the beachhead. The company and its clinical partners are actively investigating histotripsy for additional solid tumor indications, including kidney and pancreatic targets.

Funding and growth

HistoSonics has raised across multiple priced rounds over its development arc, with detailed historical round sizes scattered across SEC filings and press releases. The headline event is the 2024 majority-stake recapitalization at unicorn valuation.

That 2024 recap brought K5 Global in as the lead investor, with Bezos Expeditions and Wellington Management participating. The transaction structure (a recapitalization rather than a primary growth round) is a signal that earlier investors took partial liquidity while the company continued to operate independently with a strengthened cap table for the commercial scaling phase.

Pre-recap investors included Johnson & Johnson Innovation - JJDC, Lumira Capital, Varian (now part of Siemens Healthineers), and others across the company's growth-stage rounds. Multiple HistoSonics rounds raised tens of millions of dollars at a time as the company progressed from preclinical through pivotal clinical trials and into commercial launch.

Ann Arbor footprint

HistoSonics is headquartered in Plymouth, Michigan, with deep U-M and Michigan Medicine roots. Plymouth sits about 20 minutes east of Ann Arbor, close enough to maintain the clinical and academic collaboration that fuels the company's research pipeline while providing the industrial site footprint a regulated medical device manufacturer needs.

The Ann Arbor connection is structural. U-M Engineering produced the founding science. U-M biomedical engineering remains an active research collaborator. Michigan Medicine has been a clinical trial site and continues to be one of the leading academic medical centers using the Edison system in routine clinical care. For the regional medtech ecosystem, HistoSonics is the highest-valuation contemporary example of a U-M-rooted medical device company that scaled to commercial impact and unicorn valuation.

Why it matters

HistoSonics sits on a rare frontier in medtech: a new therapeutic modality, not an incremental improvement. If histotripsy proves out across more tumor types, the category it creates could become a standard part of oncologists' toolkits alongside surgery, radiation, chemotherapy, and immunotherapy.

Risk factors worth naming. The Edison system is a capital-equipment sale to hospitals, which is a long sales cycle and a different economic model than a SaaS business. Reimbursement for histotripsy procedures is still being established at the payer level, with CMS and commercial coverage decisions evolving. Label expansion beyond liver tumors requires additional clinical trials and separate FDA pathways. Competitors in focused ultrasound include Insightec (MR-guided HIFU), Focused Ultrasound Foundation-backed academic efforts, and a number of earlier-stage ultrasound therapy companies; Insightec in particular has the broader existing commercial footprint in MR-guided focused ultrasound for other indications.

The bull case is simple. If a non-invasive, non-thermal, image-guided method of destroying solid tumors works across multiple cancer types with favorable safety profiles, the addressable market is large, durable, and poorly served by any current alternative. The 2023 FDA De Novo clearance is the first validation of that thesis at the regulatory level. The 2024 recap is the financial market's signal that multiple serious allocators believe the thesis is durable.

For Ann Arbor specifically, HistoSonics matters because it proves the U-M medtech engine still produces unicorn outcomes. The post-Duo Ann Arbor narrative has been heavy on cybersecurity (Duo, Censys, Blumira) and AI (Voxel51, MemryX, Censys again). Medtech is the other major lane, and HistoSonics is the most valuable current commercial demonstration that lane is still active.

Hiring profile

HistoSonics hires across mechanical and electrical engineering, clinical affairs, regulatory, manufacturing, quality, field service, clinical application specialists, and commercial sales roles across the country. The software and firmware teams work on a regulated device, which changes the engineering culture. Everything moves through documented design controls, verification, and validation. This is not a "ship on Friday" environment, and roles often suit engineers who want their code and hardware to meaningfully affect patient outcomes.

Work model is primarily in-office in Plymouth, Michigan, with field roles distributed to customer hospital sites.

Related

• Esperion Therapeutics is the NASDAQ-listed Ann Arbor cardiometabolic biopharma headquartered in town, the public-market complement to HistoSonics' private unicorn story.
• Terumo Cardiovascular is the 1,000-employee global cardiovascular HQ on Jackson Road and the largest medical device employer in the region.
• Workit Health is the $118M Series C telehealth addiction treatment company on Washtenaw Avenue, the digital-first health complement to HistoSonics' device-led model.
• Ann Arbor medtech companies is the category hub.
• Ann Arbor tech companies is the master directory.

FAQ

What is histotripsy? Histotripsy is a non-invasive focused ultrasound technique that uses short, high-amplitude ultrasound pulses to mechanically destroy targeted tissue through cavitation, without heat and without incisions. HistoSonics developed the approach out of research at the University of Michigan.

Is HistoSonics FDA approved? HistoSonics' Edison system received FDA De Novo clearance in October 2023 for the non-invasive destruction of liver tumors. The company is pursuing additional indications for other solid tumors.

Is HistoSonics a unicorn? Yes. A 2024 majority-stake recapitalization led by K5 Global, with participation from Bezos Expeditions and Wellington Management, valued HistoSonics at more than $1 billion.

Where is HistoSonics headquartered? HistoSonics is headquartered in Plymouth, Michigan, with scientific and clinical roots at the University of Michigan in Ann Arbor.

How is histotripsy different from HIFU? Traditional high-intensity focused ultrasound (HIFU) relies on heating tissue. Histotripsy uses short, high-amplitude pulses to mechanically destroy tissue through cavitation, with no thermal component. That produces a sharper treatment zone and different safety characteristics.

How many patients have been treated with HistoSonics technology? As of the most recent public updates, HistoSonics reported that more than 2,000 patients had been treated using histotripsy across more than 50 US medical centers.

Who are HistoSonics' competitors? In focused ultrasound, Insightec is the most established competitor, focused on MR-guided HIFU for various indications. Other academic and earlier-stage companies are developing adjacent ultrasound therapy approaches. HistoSonics is currently the first company with FDA clearance for a histotripsy-based device.

Is HistoSonics hiring? Yes. Open roles across engineering, clinical affairs, regulatory, manufacturing, quality, and commercial functions are posted at histosonics.com/careers.